Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal and VPRIV

Shire plc SHPGY presented new data for Replagal (agalsidase alfa) in patients with Fabry disease, and VPRIV (velaglucerase alfa for injection) in patients with type 1 Gaucher disease, at the 2011 American College of Medical Genetics' (ACMG) Annual Clinical Genetics Meeting, held in Vancouver, BC, from March 16-20, 2011. Data from clinical programs evaluating the safety of switching from Fabrazyme (agalsidase beta) to Replagal and long-term safety and efficacy of switching from Cerezyme (imiglucerase) to VPRIV were presented.